Ticker Symbol: PBMD (PRR on the ASX - Australian Stock Exchange)
Upcoming Catalysts (8-8-16) - See below for more info on these catalysts.
Public float for ADR/Nasdaq: 64.90m (Per finviz.com 8-8-16) - (The current conversion rate between ASX:PRR Prima ordinary shares and Nasdaq ADRs is 30:1. This explains the big difference in share price.)
Per EOQ 6K - Prima Biomed reports A$20.88M in cash. (7/28/2016)
Prima Biomed acquired French biopharmaceutical company Immutep SA in late 2014. Immutep's pipeline is now starting to generate data.(Immutep was a small, private company when previous data has been released.)
Immutep's founder and Scientific and Medical Director, Professor Frédéric Triebel will join Prima as its Chief Scientific Officer. Frédéric Triebel
is best known for discovering the
LAG3 immune control mechanism. (Prima has fully divested from their previous drug candidate, CVAC, to focus all resources on the highly prospective Immutep/LAG3 pipeline.)
More on Frédéric Triebel https://en.wikipedia.org/wiki/Fr%C3%A9d%C3%A9ric_Triebel
More on LAG3 https://en.wikipedia.org/wiki/LAG3
LAG3 Drug Pipeline Information:
IMP321 -- IMP321 is soluble version of the immune checkpoint molecule LAG3, used to increase an immune response to tumours
Current Trials: AIPAC
- Currently in Phase IIb. IMP321 combined with Paclitaxel. Patients will be administered with subcutaneous doses of IMP321 on days 2 and 16 of a weekly regimen of paclitaxel, the day after their paclitaxel infusion for six months.
ClinicalTrials.gov trial link --> https://clinicaltrials.gov/ct2/show/NCT02614833?term=AIPAC&rank=1
Phase IIa results TACTI-MEL
- Currently in Phase I. Two ACTive Immunotherapeutics in melanoma will be a safety and dose finding IMP321 study.
IMP321 will be combined with Merck's blockbuster drug Keytruda (Pembrolizumab).
ClinicalTrials.gov link --> https://clinicaltrials.gov/ct2/show/NCT02676869?term=tacti-mel&rank=1
Pre-clinical results from combining anti-lag3 agents (IMP321) with anti-PD-1 inhibitor therapies (Keytruda) have yielded impressive results. http://www.onclive.com/conference-coverage/smr-2015/new-treatments-for-novel-targets-next-step-in-immuno-oncology-revolution
More information regarding TACTI-MEL from Edison:
These results have prompted Bristol Myers Squibb BMY to start a similar trial with their anti-PD-1 blockbuster drug Opdivo combinded with their LAG3 developmental drug thus validating Prima's TACTI-MEL and LAG3 which was discovered by Prima's CSO Frédéric Triebel
. https://www.mskcc.org/cancer-care/clinical-trials/14-010 https://clinicaltrials.gov/ct2/show/NCT01968109 INSIGHT
- a new collaborative study investigating the intra-tumoural injection of IMP321. The new study will explore the potential for IMP321 as an activator of dendritic cells found within solid cancer tumours. http://finance.yahoo.com/news/prima-biomed-collaborates-investigator-sponsored-073742130.html Collaboration with NEC Corporation and Yamaguchi University in Japan http://finance.yahoo.com/news/prima-biomed-progresses-japanese-collaboration-120000144.html
Latest data from the collaboration published in April 2016 in the Journal Cancer Science
Wiley Online Library - http://onlinelibrary.wiley.com/doi/10.1111/cas.12861/full
IMP731 - IMP731 is a depleting antibody for autoimmune disease that targets LAG3+ activated T cells. IMP731 is under development by partner Glaxo-Smith-Kline (GSK).
There is evidence, in the tuberculin-induced DTH model in primates, that a single injection of a depleting LAG-3 monoclonal antibody can prevent Th1-driven skin inflammation. (Plaque Psoriasis)
ClinicalTrials.gov link --> https://clinicaltrials.gov/ct2/show/NCT02195349?term=GSK2831781&rank=1
IMP701 - IMP701 is an anti-LAG-3 antibody which blocks LAG-3-mediated immune down-regulation. The product was originally licensed in 2012 to the American biotech company CoStim. That company was acquired by Novartis (NVS) in 2014. http://www.streetinsider.com/Corporate+News/Prima+BioMed+%28PBMD%29+to+Receive+Phase+I+IMP701+LAG-3+Antibody-Related+Milestone+Payment+from+Novartis+%28NVS%29/10814636.html
ClinicalTrials.gov link --> https://clinicaltrials.gov/ct2/show/NCT02460224?term=lag525&rank=1
Chair of Board is Lucy Turnbull, the wife of Malcolm Turnbull who is the Prime Minister of Australia. https://en.wikipedia.org/wiki/Lucy_Turnbull https://en.wikipedia.org/wiki/Malcolm_Turnbull
Recent Analysts Upgrades:
|May-12-16 ||Reiterated ||Maxim Group ||Buy ||$4 → $5 |
|Apr-19-16 ||Initiated ||Maxim Group ||Buy ||$4 |
|Dec-31-15 ||Initiated ||ROTH Capital ||Buy ||$6 |
|Dec-03-15 ||Initiated ||FBR Capital ||Outperform ||$6 |
|Oct-14-15 ||Initiated ||H.C. Wainwright ||Buy ||$3 |